Analyst Take: Following the USDA’s approval of CCM in Q2 2023, UPSIDE's cultivated chicken was featured in a six-course meal at Bar Cren in New York in August, priced at USD 150, and Chef José Andrés served Good Meat's cultivated chicken at China Chilcano in Washington, DC, marking lab-grown meat’s commercial debut in the US. However, this doesn't imply that lab-grown meat will be available in supermarkets immediately. Currently, both companies have received permission to exclusively sell chicken products at a limited number of restaurants. They would also require further approval to introduce cell-cultured beef, pork, or seafood to the market.
Analyst Take: PBM market activity (market entry and market penetration activities) continued to slow down, but retail expansions remained steady, with notable developments from Everything Legendary and Konscious Foods. Outside the US, unMEAT made significant strides with its expansion into Australia. PBD&E distribution expansions reached their lowest levels in the past five quarters, following two standout quarters in Q1 and Q4 2022, although Veg of Lund made significant progress with its entry into the Asian market.
Analyst Take: Partnerships in the PBM and PBD&E industries mostly centered around final form products, with several firms like Impossible Foods, Beyond Meat, and The Raging Pig collaborating to introduce new menu items for foodservice. Furthermore, multiple disruptors secured distribution agreements for foodservice and retail across the US (Meati) and Europe (Oatly, Redefine Meat, and THIS). In the emerging cell-cultured segment, a focus on R&D was evident, led by Steakholder Foods, which partnered with a GCC governmental body to commercialize 3D bioprinting technology.
Analyst Take: PBM funding continued to decrease on the back of the industry's gloomy outlook, underpinned by higher prices and issues related to taste, texture, and quality.PBD&E funding showed a slight recovery during the quarter, reaching USD 18 million (from USD 8 million in Q2 2023). However, this was notably lower compared with USD 53 million a year ago. The other alternative foods category rebounded from its Q2 2023 dip, securing USD 27 million across seven funding rounds (compared with USD 175,000 in the last quarter from a single round).
Analyst Take: Some regulators, like in the UK, aim to streamline their regulatory processes by removing unnecessary steps to simplify approval, while France is challenging regulations on labeling for plant-based meat products. In the midst of this, alternative protein companies, such as Nature's Fynd and Imagindairy, successfully obtained regulatory approval for their products during the quarter.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.